Acorda Therapeutics Inc (ACOR.O) News| Reuters.com
Edition:
United States

Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

24.48USD
27 Jun 2016
Change (% chg)

-- (--)
Prev Close
$24.48
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
735,690
52-wk High
$43.63
52-wk Low
$23.85

Select another date:

Thu, Jun 9 2016

BRIEF-Acorda presents phase 1 data on Migraine drug at 58th annual meeting of American Headache Society

* There were no serious adverse events, dose limiting toxicities, study discontinuations due to adverse events reported for cvt-427

BRIEF-Biotie Therapies: final results of subsequent offer period of Acorda's tender offer

* Final results of the subsequent offer period of Acorda's tender offer for all securities in Biotie

BRIEF-Acorda announces results from mid-phase clinical trial of CVT-301

* Acorda Announces Results From Phase 2b Clinical Trial Of CVT 301 for treatment of off periods in parkinson's disease published in movement disorders

BRIEF-Acorda Therapeutics: results of tender offer for Biotie Therapies

* Says tender offer for Biotie Therapies Corp expired on April 8

BRIEF-Biotie Therapies U.S. antitrust regulation relating to tender offer expires

* U.S. antitrust regulation waiting period relating to tender offer has expired

Acorda to buy Finland's Biotie for $363 million

HELSINKI U.S. biotechnology company Acorda Therapeutics Inc. announced on Tuesday an agreed $363 million cash bid for all of the shares in Finland's Biotie Therapies .

U.S. firm Acorda to buy Finland's Biotie for $363 million

HELSINKI, Jan 19 U.S. biotechnology company Acorda Therapeutics Inc. announced on Tuesday an agreed $363 million cash bid for all of the shares in Finland's Biotie Therapies.

BRIEF-Biotie Therapies and Acorda Therapeutics enter into combination agreement

* Says Acorda Therapeutics and Biotie Therapies have entered into combination agreement

Select another date: